Cell-penetrating peptides and their utility in genome function modifications (Review)
- Authors:
- Maciej Gagat
- Wioletta Zielińska
- Alina Grzanka
-
Affiliations: Department of Histology and Embryology, Faculty of Medicine, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Pl-85-092 Bydgoszcz, Poland - Published online on: October 4, 2017 https://doi.org/10.3892/ijmm.2017.3172
- Pages: 1615-1623
-
Copyright: © Gagat et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Zorko M and Langel U: Cell-penetrating peptides: Mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev. 57:529–545. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Karro K, Männik T, Männik A and Ustav M: DNA transfer into animal cells using stearylated CPP based transfection reagent. Methods Mol Biol. 1324:435–445. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ramakrishna S, Kwaku Dad A-BB, Beloor J, Gopalappa R, Lee SK and Kim H: Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. 24:1020–1027. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zatsepin TS, Turner JJ, Oretskaya TS and Gait MJ: Conjugates of oligonucleotides and analogues with cell penetrating peptides as gene silencing agents. Curr Pharm Des. 11:3639–3654. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Segovia N, Dosta P, Cascante A, Ramos V and Borrós S: Oligopeptide-terminated poly(β-amino ester)s for highly efficient gene delivery and intracellular localization. Acta Biomater. 10:2147–2158. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu C, Luo Q, Tu Y, Wang G, Liu Y and Xie Y: Drug-carrier interaction analysis in the cell penetrating peptide-modified liposomes for doxorubicin loading. J Microencapsul. 32:745–754. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Wen G, Wang D, Zhang X, Lu Y, Wang J, Zhong L, Cai H, Zhang X and Wang Y: A complementary strategy for enhancement of nanoparticle intracellular uptake. Pharm Res. 31:2054–2064. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jo J, Hong S, Choi WY and Lee DR: Cell-penetrating peptide (CPP)-conjugated proteins is an efficient tool for manipulation of human mesenchymal stromal cells. Sci Rep. 4:43782014. View Article : Google Scholar : PubMed/NCBI | |
|
Khafagy S, Morishita M, Isowa K, Imai J and Takayama K: Effect of cell-penetrating peptides on the nasal absorption of insulin. J Control Release. 133:103–108. 2009. View Article : Google Scholar | |
|
Skotland T, Iversen TG, Torgersen ML and Sandvig K: Cell-penetrating peptides: Possibilities and challenges for drug delivery in vitro and in vivo. Molecules. 20:13313–13323. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Frankel AD and Pabo CO: Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 55:1189–1193. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Green M and Loewenstein PM: Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell. 55:1179–1188. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Ruben S, Perkins A, Purcell R, Joung K, Sia R, Burghoff R, Haseltine WA and Rosen CA: Structural and functional characterization of human immunodeficiency virus tat protein. J Virol. 63:1–8. 1989.PubMed/NCBI | |
|
Derossi D, Joliot AH, Chassaing G and Prochiantz A: The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem. 269:10444–10450. 1994.PubMed/NCBI | |
|
Milletti F: Cell-penetrating peptides: Classes, origin, and current landscape. Drug Discov Today. 17:850–860. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Derossi D, Chassaing G and Prochiantz A: Trojan peptides: The penetratin system for intracellular delivery. Trends Cell Biol. 8:84–87. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Pooga M, Hällbrink M, Zorko M and Langel U: Cell penetration by transportan. FASEB J. 12:67–77. 1998.PubMed/NCBI | |
|
Kwon SJ, Han K, Jung S, Lee JE, Park S, Cheon YP and Lim HJ: Transduction of the MPG-tagged fusion protein into mammalian cells and oocytes depends on amiloride-sensitive endocytic pathway. BMC Biotechnol. 9:732009. View Article : Google Scholar : PubMed/NCBI | |
|
Mo RH, Zaro JL and Shen WC: Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy. Mol Pharm. 9:299–309. 2012. View Article : Google Scholar : | |
|
Bechara C, Pallerla M, Burlina F, Illien F, Cribier S and Sagan S: Massive glycosaminoglycan-dependent entry of Trp-containing cell-penetrating peptides induced by exogenous sphingomyelinase or cholesterol depletion. Cell Mol Life Sci. 72:809–820. 2015. View Article : Google Scholar | |
|
Melikov K, Hara A, Yamoah K, Zaitseva E, Zaitsev E and Chernomordik LV: Efficient entry of cell-penetrating peptide nona-arginine into adherent cells involves a transient increase in intracellular calcium. Biochem J. 471:221–230. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zavaglia D, Favrot MC, Eymin B, Tenaud C and Coll JL: Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein. Gene Ther. 10:314–325. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Lin YZ, Yao SY, Veach RA, Torgerson TR and Hawiger J: Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem. 270:14255–14258. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Oehlke J, Krause E, Wiesner B, Beyermann M and Bienert M: Extensive cellular uptake into endothelial cells of an amphipathic beta-sheet forming peptide. FEBS Lett. 415:196–199. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Rousselle C, Clair P, Temsamani J and Scherrmann JM: Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy. J Drug Target. 10:309–315. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Järver P and Langel U: Cell-penetrating peptides - a brief introduction. Biochim Biophys Acta. 1758:260–263. 2006. View Article : Google Scholar | |
|
Meade BR and Dowdy SF: Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev. 59:134–140. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Simeoni F, Morris MC, Heitz F and Divita G: Insight into the mechanism of the peptide-based gene delivery system MPG: Implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. 31:2717–2724. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Muñoz-Morris MA, Heitz F, Divita G and Morris MC: The peptide carrier Pep-1 forms biologically efficient nanoparticle complexes. Biochem Biophys Res Commun. 355:877–882. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Gros E, Deshayes S, Morris MC, Aldrian-Herrada G, Depollier J, Heitz F and Divita G: A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Biochim Biophys Acta. 1758:384–393. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Deshayes S, Morris M, Heitz F and Divita G: Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv Drug Deliv Rev. 60:537–547. 2008. View Article : Google Scholar | |
|
Guo Z, Peng H, Kang J and Sun D: Cell-penetrating peptides: Possible transduction mechanisms and therapeutic applications. Biomed Rep. 4:528–534. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mäger I, Langel K, Lehto T, Eiríksdóttir E and Langel U: The role of endocytosis on the uptake kinetics of luciferin-conjugated cell-penetrating peptides. Biochim Biophys Acta. 1818:502–511. 2012. View Article : Google Scholar | |
|
Dutta D and Donaldson JG: Search for inhibitors of endocytosis: Intended specificity and unintended consequences. Cell Logist. 2:203–208. 2012. View Article : Google Scholar | |
|
Tomoda H, Kishimoto Y and Lee YC: Temperature effect on endocytosis and exocytosis by rabbit alveolar macrophages. J Biol Chem. 264:15445–15450. 1989.PubMed/NCBI | |
|
Bode SA1, Thévenin M, Bechara C, Sagan S, Bregant S, Lavielle S, Chassaing G and Burlina F: Self-assembling mini cell-penetrating peptides enter by both direct translocation and glycosaminoglycan-dependent endocytosis. Chem Commun (Camb). 48:7179–7181. 2012. View Article : Google Scholar | |
|
Cleal K, He L, Watson PD and Jones AT: Endocytosis, intracellular traffic and fate of cell penetrating peptide based conjugates and nanoparticles. Curr Pharm Des. 19:2878–2894. 2013. View Article : Google Scholar | |
|
Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G and Prochiantz A: Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem. 271:18188–18193. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Matsuzaki K, Sugishita K and Miyajima K: Interactions of an antimicrobial peptide, magainin 2, with lipopolysaccharide-containing liposomes as a model for outer membranes of gram-negative bacteria. FEBS Lett. 449:221–224. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Deshayes S, Plénat T, Aldrian-Herrada G, Divita G, Le Grimellec C and Heitz F: Primary amphipathic cell-penetrating peptides: Structural requirements and interactions with model membranes. Biochemistry. 43:7698–7706. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Regberg J, Eriksson JN and Langel U: Cell-penetrating peptides: From cell cultures to in vivo applications. Front Biosci (Elite Ed). 5:509–516. 2013. View Article : Google Scholar | |
|
Safety and efficacy study of AVI-5126 when used on vein grafts before use in heart by-pass graft surgery (CABG). https://clinicaltrials.gov/ct2/show/NCT00451256. 2009 | |
|
Safety and efficacy study of KAI-1678 to treat pain in subjects with postherpetic neuralgia. https://clinicaltrials.gov/ct2/show/NCT01106716. 2010 | |
|
Safety and efficacy study of KAI-1678 to treat pain in subjects with spinal cord injury. https://clinicaltrials.gov/ct2/show/NCT01135108. 2010 | |
|
Safety and efficacy study of KAI-1678 to treat subjects with postoperative pain. https://clinicaltrials.gov/ct2/show/NCT01015235. 2011 | |
|
Efficacy of AM-111 in patients with acute sensorineural hearing loss. https://clinicaltrials.gov/ct2/show/NCT00802425. 2014 | |
|
Safety and efficacy study of RT001 to treat moderate to severe lateral canthal lines. https://clinicaltrials.gov/ct2/show/NCT00888914. 2013 | |
|
Safety, tolerability and PK of a single iv infusion of 10, 40, and 80 µg/kg XG-102 administered to healthy volunteers. https://clinicaltrials.gov/ct2/show/NCT01570205. 2012 | |
|
Efficacy and safety of XG-102 in reduction of post-cataract surgery intraocular inflammation. https://clinicaltrials.gov/ct2/show/NCT02235272. 2015 | |
|
AM-111 in the treatment of acute inner ear hearing loss (HEALOS). https://clinicaltrials.gov/ct2/show/NCT02561091. 2014 | |
|
Efficacy and safety of AM-111 as acute sudden sensorineural hearing loss treatment (ASSENT). https://clinicaltrials.gov/ct2/show/NCT02809118. 2017 | |
|
Bakhtiyari S, Haghani K, Basati G and Karimfar MH: siRNA therapeutics in the treatment of diseases. Ther Deliv. 4:45–57. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Nakase I, Tanaka G and Futaki S: Cell-penetrating peptides (CPPs) as a vector for the delivery of siRNAs into cells. Mol Biosyst. 9:855–861. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wierzbicki PM, Kogut-Wierzbicka M, Ruczynski J, Siedlecka-Kroplewska K, Kaszubowska L, Rybarczyk A, Alenowicz M, Rekowski P and Kmiec Z: Protein and siRNA delivery by transportan and transportan 10 into colorectal cancer cell lines. Folia Histochem Cytobiol. 52:270–280. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Moschos SA, Jones SW, Perry MM, Williams AE, Erjefalt JS, Turner JJ, Barnes PJ, Sproat BS, Gait MJ and Lindsay MA: Lung delivery studies using siRNA conjugated to TAT(48–60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem. 18:1450–1459. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Turner JJ, Jones S, Fabani MM, Ivanova G, Arzumanov AA and Gait MJ: RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cells Mol Dis. 38:1–7. 2007. View Article : Google Scholar | |
|
Muratovska A and Eccles MR: Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 558:63–68. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Davidson TJ, Harel S, Arboleda VA, Prunell GF, Shelanski ML, Greene LA and Troy CM: Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. J Neurosci. 24:10040–10046. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Chiu YL, Ali A, Chu CY, Cao H and Rana TM: Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol. 11:1165–1175. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Turner JJ, Williams D, Owen D and Gait MJ: Disulfide conjugation of peptides to oligonucleotides and their analogs. Current protocols in nucleic acid chemistry. Chapter 4: Unit 4.28. 2006. View Article : Google Scholar | |
|
Huang YW, Lee HJ, Tolliver LM and Aronstam RS: Delivery of nucleic acids and nanomaterials by cell-penetrating peptides: Opportunities and challenges. Biomed Res Int. 2015:8340792015.PubMed/NCBI | |
|
Crowet JM, Lins L, Deshayes S, Divita G, Morris M, Brasseur R and Thomas A: Modeling of non-covalent complexes of the cell-penetrating peptide CADY and its siRNA cargo. Biochim Biophys Acta. 1828:499–509. 2013. View Article : Google Scholar | |
|
Crombez L, Morris MC, Dufort S, Aldrian-Herrada G, Nguyen Q, Mc Master G, Coll JL, Heitz F and Divita G: Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res. 37:4559–4569. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kadkhodayan S, Jafarzade BS, Sadat SM, Motevalli F, Agi E and Bolhassani A: Combination of cell penetrating peptides and heterologous DNA prime/protein boost strategy enhances immune responses against HIV-1 Nef antigen in BALB/c mouse model. Immunol Lett. 188:38–45. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bivalkar-Mehla S, Mehla R and Chauhan A: Chimeric peptide-mediated siRNA transduction to inhibit HIV-1 infection. J Drug Target. 25:307–319. 2017. View Article : Google Scholar | |
|
Kato T, Yamashita H, Misawa T, Nishida K, Kurihara M, Tanaka M, Demizu Y and Oba M: Plasmid DNA delivery by arginine-rich cell-penetrating peptides containing unnatural amino acids. Bioorg Med Chem. 24:2681–2687. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rudolph C, Plank C, Lausier J, Schillinger U, Müller RH and Rosenecker J: Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J Biol Chem. 278:11411–11418. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Rádis-Baptista G, Campelo IS, Morlighem JR, Melo LM and Freitas VJ: Cell-penetrating peptides (CPPs): From delivery of nucleic acids and antigens to transduction of engineered nucleases for application in transgenesis. J Biotechnol. 252:15–26. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Nagy A: Cre recombinase: The universal reagent for genome tailoring. Genesis. 26:99–109. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Jo D, Nashabi A, Doxsee C, Lin Q, Unutmaz D, Chen J and Ruley HE: Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase. Nat Biotechnol. 19:929–933. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Wadia JS, Stan RV and Dowdy SF: Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med. 10:310–315. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hashimoto M, Taniguchi M, Yoshino S, Arai S and Sato K: S Phase-preferential Cre-recombination in mammalian cells revealed by HIV-TAT-PTD-mediated protein transduction. J Biochem. 143:87–95. 2008. View Article : Google Scholar | |
|
Xu Y, Liu S, Yu G, Chen J, Chen J, Xu X, Wu Y, Zhang A, Dowdy SF and Cheng G: Excision of selectable genes from transgenic goat cells by a protein transducible TAT-Cre recombinase. Gene. 419:70–74. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
De Coupade C, Fittipaldi A, Chagnas V, Michel M, Carlier S, Tasciotti E, Darmon A, Ravel D, Kearsey J, Giacca M, et al: Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochem J. 390:407–418. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gitton Y, Tibaldi L, Dupont E, Levi G and Joliot A: Efficient CPP-mediated Cre protein delivery to developing and adult CNS tissues. BMC Biotechnol. 9:402009. View Article : Google Scholar : PubMed/NCBI | |
|
Sonsteng KM, Prigge JR, Talago EA, June RK and Schmidt EE: Hydrodynamic delivery of Cre protein to lineage-mark or time-stamp mouse hepatocytes in situ. PLoS One. 9:e912192014. View Article : Google Scholar : PubMed/NCBI | |
|
Gaj T, Guo J, Kato Y, Sirk SJ and Barbas CF III: Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat Methods. 9:805–807. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z, Jaafar L, Agyekum DG, Xiao H, Wade MF, Kumaran RI, Spector DL, Bao G, Porteus MH, Dynan WS, et al: Receptor-mediated delivery of engineered nucleases for genome modification. Nucleic Acids Res. 41:e1822013. View Article : Google Scholar : PubMed/NCBI | |
|
Cornu TI, Thibodeau-Beganny S, Guhl E, Alwin S, Eichtinger M, Joung JK and Cathomen T: DNA-binding specificity is a major determinant of the activity and toxicity of zinc-finger nucleases. Mol Ther. 16:352–358. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Pruett-Miller SM, Reading DW, Porter SN and Porteus MH: Attenuation of zinc finger nuclease toxicity by small-molecule regulation of protein levels. PLoS Genet. 5:e10003762009. View Article : Google Scholar : PubMed/NCBI | |
|
Puria R, Sahi S and Nain V: HER2+ breast cancer therapy: By CPP-ZFN mediated targeting of mTOR? Technol Cancer Res Treat. 11:175–180. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nain V, Sahi S and Verma A: CPP-ZFN: A potential DNA-targeting anti-malarial drug. Malar J. 9:2582010. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Gaj T, Patterson JT, Sirk SJ and Barbas CF III: Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering. PLoS One. 9:e857552014. View Article : Google Scholar : PubMed/NCBI | |
|
Horvath P and Barrangou R: CRISPR/Cas, the immune system of bacteria and archaea. Science. 327:167–170. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Selle K and Barrangou R: Harnessing CRISPR-Cas systems for bacterial genome editing. Trends Microbiol. 23:225–232. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Harms DW, Quadros RM, Seruggia D, Ohtsuka M, Takahashi G, Montoliu L and Gurumurthy CB: Mouse genome editing using the CRISPR/Cas system. Curr Protoc Hum Genet. 83:15.7.1–15.7.27. 2014. View Article : Google Scholar | |
|
Bortesi L and Fischer R: The CRISPR/Cas9 system for plant genome editing and beyond. Biotechnol Adv. 33:41–52. 2015. View Article : Google Scholar | |
|
Park A, Hong P, Won ST, Thibault PA, Vigant F, Oguntuyo KY, Taft JD and Lee B: Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing. Mol Ther Methods Clin Dev. 3:160572016. View Article : Google Scholar : PubMed/NCBI | |
|
Suresh B, Ramakrishna S and Kim H: Cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA for genome editing. Methods Mol Biol. 1507:81–94. 2017. View Article : Google Scholar | |
|
Langel U: Handbook of Cell-Penetrating Peptides. 2nd edition. Taylor and Francis Group; 2006, View Article : Google Scholar | |
|
Saar K, Lindgren M, Hansen M, Eiríksdóttir E, Jiang Y, Rosenthal-Aizman K, Sassian M and Langel U: Cell-penetrating peptides: A comparative membrane toxicity study. Anal Biochem. 345:55–65. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Suhorutsenko J, Oskolkov N, Arukuusk P, Kurrikoff K, Eriste E, Copolovici DM and Langel U: Cell-penetrating peptides, PepFects, show no evidence of toxicity and immunogenicity in vitro and in vivo. Bioconjug Chem. 22:2255–2262. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Amantana A, Moulton HM, Cate ML, Reddy MT, Whitehead T, Hassinger JN, Youngblood DS and Iversen PL: Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug Chem. 18:1325–1331. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Maiolo JR, Ferrer M and Ottinger EA: Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating peptides. Biochim Biophys Acta. 1712:161–172. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Cox DB, Platt RJ and Zhang F: Therapeutic genome editing: Prospects and challenges. Nat Med. 21:121–131. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yin H, Song CQ, Dorkin JR, Zhu LJ, Li Y, Wu Q, Park A, Yang J, Suresh S, Bizhanova A, et al: Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol. 34:328–333. 2016. View Article : Google Scholar : PubMed/NCBI |
